64, Avenue de la Roseraie
1205, Genève - Switzerland
‚Äč

+41 223 794 643

info@neurix.ch

BACK TO THE TOP

© 2019 by Neurix SA

Neurix is strategically interested in industrial and academic partnerships with high potential and commercialisation opportunities. We have been and still are active on multiple international projects for the development of next generation Multiple Sclerosis and Alzheimer's disease in vitro models.

ACTIVE INNOVATION

PIPELINE

Deliverables, Objectives and Products

Multiple

Sclerosis

Alzheimer's Disease

Guillain-Barré Syndrome

Treatment

Chronic Septic Granulomatosis disease

RosaGBS in frame

of Eurostars

The Swiss-Swedish project addresses an immunological mechanism that needs external expertise for further development of treatment of the rare autoimmune disease Guillain-Barré Syndrome (GBS) with unique molecules developed by PRONOXIS company. The project will bring new drug candidates to clinical trial for GBS using a new immunological mechanism. Neurix offers human in vitro neural tissues to accelerate the drug development and test neurotoxicity of newly developed interventions, Reactive Oxygen Species (ROS) Activators.

Multiple Sclerosis
in frame of Horizon 2020

Multiple sclerosis is a leading cause of neurological disability among young adults, resulting from an autoimmune reaction against myelin and neurodegeneration. The consortium consisting of universities and companies across 11 European countries and the US will unite efforts to tailor the development and application of therapies to the individual MS patient within 5 years. The Neurix mission is to generate a new 3D human in vitro based model for testing of novel MS therapeutical interventions targeting demand from industry: neurorepair and myelin restoration.

Alzheimer Disease

Swiss-South Korean

collaboration

Understanding AD development is not only a key challenge for researchers but also for the wider society, given the rapidly aging populations in developed countries. Advances in this field require new tools with which to recreate neural tissue in vitro and produce realistic disease models. The Swiss-South Korean joint project “Alzheimer`s Kit&Screen” aims to develop a novel diagnostic kit and drug screening assays for Alzheimer’s disease (AD) within 3 years. The diagnostic kit will be developed based on newly identified biomarkers. Human in vitro neural models of AD in 3D (AD minibrains) will be created from the different types of iPSC thereby respond to the need expressed by industry. During the project, the drug screening potential of these in vitro models will be validated.

CELESTE Chronic Septic Granulomatosis

Swiss-French consortium

Thanks to complementarity expertise between French and Swiss partners, the CELESTE consortium is aimed to accelerate the development of new immunotherapeutic for Chronic Septic Granulomatosis disease. The approach will be based on modeling inflammatory disease by establishment of new in vitro screening test based on patient-derived human induced pluripotent stem cells. Neurix perform a quality control of iPSCs-derived human hematopoietic stem cells from patient and their ability to differentiate to different types of blood cells. The new interventions/therapeutic applications affecting their differentiation potential will be tested.